Scholars@Duke
Thomas Rodgers
Manage Profile
Embed Profile Data

Selected Publications

Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies.

Journal Article Oncol Ther · December 2021 Chemoimmunotherapy with rituximab (R-chemo) or obinutuzumab (G-chemo) is standard of care for patients with previously untreated symptomatic or high-tumor-burden follicular lymphoma. Median progression-free survival (PFS) with R-chemo plus R maintenance ex ... Full text Link to item Cite

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Journal Article Clin Cancer Res · November 15, 2021 PURPOSE: Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, in combination with lenalidomide, demonstrated efficacy in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in the single-ar ... Full text Link to item Cite

Identifying and Overcoming Barriers in Clinical Trial Enrollment for Veterans with Blood Cancers

Conference Blood · November 5, 2021 AbstractIntroductionEquitable and diverse clinical trials participation is essential for practice-changing results to be applicable to all patients. However, patients who ide ... Full text Cite

Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis

Conference Blood · November 5, 2021 AbstractBackgroundPrimary bone diffuse large B cell lymphoma (DLBCL) is a variant of extranodal non-Hodgkin lymphoma (NHL) that is relatively rare, accounting for 3-15% of ex ... Full text Cite

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Journal Article Leuk Lymphoma · March 2021 Phosphoinositide-3-kinase (PI3K) inhibitors have efficacy in lymphoid malignancies; however, inflammatory and infectious toxicities can compromise the treatment course. An improved understanding of these toxicities will guide clinical use and further devel ... Full text Link to item Cite

Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma.

Journal Article Hematol Oncol Clin North Am · October 2020 Survival for patients with mantle cell lymphoma has improved dramatically over the last 2 decades owing to a better understanding of disease biology and the development of more effective treatment regimens for patients with untreated and relapsed disease. ... Full text Link to item Cite

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.

Journal Article Clin Cancer Res · July 15, 2020 PURPOSE: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. EXPERIMENTAL DESIGN: ... Full text Link to item Cite

RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Journal Article Journal of Clinical Oncology · May 20, 2020 8020 Background: Patients with R/R DLBCL ineligible for autologous stem cell transplant (ASCT) have a poor prognosis. In these patients, tafasitamab (anti-CD19 antibody) plus lenalidomide (LEN) has shown encouraging results in th ... Full text Cite

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Conference Blood · November 13, 2019 Introduction: Venetoclax (VEN) based therapy has become a standard of care in front line and relapsed-refractory (R/R) CLL based on favorable efficacy and toxicity. Whereas prospective data regarding activity of therapies following ibrutinib (IBR) ... Full text Cite

Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.

Journal Article Journal of Clinical Oncology · May 20, 2019 7547 Background: Outcomes remain poor for patients with relapsed refractory DLBCL and HGBCL, especially those ineligible for a stem cell transplant or CAR T-cell therapy. Lenalidomide has efficacy in these groups, most notably in ... Full text Cite

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.

Journal Article Expert Opin Emerg Drugs · June 2018 The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatmen ... Full text Link to item Cite

Pitfalls of Combining Novel Agents in Lymphoma.

Journal Article Curr Treat Options Oncol · May 28, 2018 As our knowledge of lymphoma and its intricate signaling pathways has grown, so has the development of novel agents. While their mechanisms of action vary considerably, these therapies supplement and in some cases offer alternatives to standard chemotherap ... Full text Link to item Cite

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.

Journal Article PLoS One · 2017 INTRODUCTION: Carboplatin is widely used to treat lung cancer in the United States as an alternative to cisplatin. Several studies have demonstrated that cisplatin-based regimen is associated with a high frequency of thromboembolic complications. However, ... Full text Link to item Cite